Neuroendocrine neoplasms of the pancreas: diagnosis and pitfalls

Virchows Arch. 2022 Feb;480(2):247-257. doi: 10.1007/s00428-021-03211-5. Epub 2021 Oct 13.

Abstract

Common to neuroendocrine neoplasms of the pancreas is their expression of synaptophysin, chromogranin A, and/or INSM1. They differ, however, in their histological differentiation and molecular profile. Three groups can be distinguished: well-differentiated neuroendocrine neoplasms (neuroendocrine tumors), poorly differentiated neuroendocrine neoplasms (neuroendocrine carcinomas), and mixed neuroendocrine-non-neuroendocrine neoplasms. However, the expression of synaptophysin and, to a lesser extent, also chromogranin A is not restricted to the neuroendocrine neoplasms, but may also be in a subset of non-neuroendocrine epithelial and non-epithelial neoplasms. This review provides the essential criteria for the diagnosis of pancreatic neuroendocrine neoplasms including diagnostic clues for the distinction of high-grade neuroendocrine tumors from neuroendocrine carcinomas and an algorithm avoiding diagnostic pitfalls in the delineation of non-neuroendocrine neoplasms with neuroendocrine features from pancreatic neuroendocrine neoplasms.

Keywords: Diagnosis; Histology; Immunohistology; Pancreatic neuroendocrine neoplasms; Pitfalls.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / metabolism
  • Carcinoma, Neuroendocrine* / diagnosis
  • Carcinoma, Neuroendocrine* / pathology
  • Chromogranin A
  • Humans
  • Immunohistochemistry
  • Neuroendocrine Tumors* / pathology
  • Pancreas / metabolism
  • Pancreas / pathology
  • Pancreatic Neoplasms* / diagnosis
  • Repressor Proteins / metabolism
  • Synaptophysin / metabolism

Substances

  • Biomarkers, Tumor
  • Chromogranin A
  • Repressor Proteins
  • Synaptophysin
  • INSM1 protein, human